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OBJECTIVE—Glycated hemoglobin was recently recom-
mended for use as a diagnostic test for diabetes. We examined
the association between 2010 American Diabetes Association
diagnostic cut points for glycated hemoglobin and microvascular
outcomes (chronic kidney disease, end-stage renal disease
[ESRD], and retinopathy) and formally tested for the presence of
risk thresholds in the relationships of glycated hemoglobin with
these outcomes.
RESEARCH DESIGN AND METHODS—Prospective cohort
and cross-sectional analyses of 11,357 participants (773 with a
history of diagnosed diabetes) from the Atherosclerosis Risk in
Communities (ARIC) Study.
RESULTS—During a median of 14 years of follow-up of individ-
uals without diagnosed diabetes at baseline, clinical categories of
glycated hemoglobin were associated with risk of chronic kidney
disease, with adjusted hazard ratios (HRs) of 1.12 (0.94–1.34) and
1.39 (1.04–1.85) for glycated hemoglobin 5.7–6.4% and 6.5%,
respectively, as compared with 5.7% (P trend  0.002). The
corresponding HRs for ESRD were 1.51 (0.82–2.76) and 1.98
(0.83–4.73), respectively (P trend  0.047). In the absence of
diagnosed diabetes, glycated hemoglobin was cross sectionally
associated with the presence of moderate/severe retinopathy,
with adjusted odds ratios of 1.42 (0.69–2.92) and 2.91 (1.19–7.11)
for glycated hemoglobin 5.7–6.5% and 6.5%, respectively,
compared with 5.7% (P trend  0.011). Risk associations were
stronger among individuals with a history of diabetes. We did not
observe signiﬁcant thresholds in the associations of glycated
hemoglobin with kidney disease risk or retinopathy.
CONCLUSIONS—These data from a community-based, biracial
population support the use of new 2010 American Diabetes
Association glycated hemoglobin cut points for the diagnosis of
diabetes. Diabetes 60:298–305, 2011
M
easurement of glycated hemoglobin has long
been central to the management and treat-
ment of diabetes. The evidence for the use of
glycated hemoglobin in clinical practice is
largely based on its associations with retinopathy in
observational studies (1–5) and clinical trial data demon-
strating that lowering glycated hemoglobin can prevent
microvascular outcomes in individuals with diabetes (6–
10). Diagnostic criteria for diabetes have been traditionally
based exclusively on fasting or 2-h glucose testing. In a
major change to clinical practice, the 2010 guidelines from
the American Diabetes Association recommend the use of
glycated hemoglobin as a diagnostic test for diabetes (11),
with 6.5% designated as the diagnostic threshold. How-
ever, few studies have investigated the relationship of new
glycated hemoglobin cut points with microvascular
disease.
The objective of this study was to characterize the
associations of glycated hemoglobin with risk of kidney
disease and retinopathy in a community-based population.
We compared these associations to those for fasting
glucose. We hypothesized that among individuals without
a history of diabetes, new American Diabetes Association
cut points for glycated hemoglobin would identify risk for
future kidney disease and would be cross-sectionally
associated with prevalent retinopathy. We undertook anal-
yses to characterize the shapes of the associations and to
formally test for the presence of possible threshold effects
in these data.
RESEARCH DESIGN AND METHODS
The Atherosclerosis Risk in Communities (ARIC) Study is a community-based
prospective cohort study of 15,792 middle-aged adults sampled from four U.S.
communities. The ﬁrst clinic examinations (visit 1) took place during 1987–
1989, with three follow-up visits approximately every 3 years (12). Visit 2
(1990–1992) was the only visit for which stored whole blood samples were
available for measurement of HbA1c, and it is the baseline for the present
study. There were 14,348 participants who attended visit 2.
For our analyses of kidney outcomes, we excluded participants who had a
recorded race/ethnicity other than white or black, history of cardiovascular
disease or kidney disease, or who were nonfasting or who were missing
variables of interest, for a ﬁnal sample size of 11,357. Among these partici-
pants, 773 (6.8%) had a self-reported diagnosis of diabetes or were taking
medication for diabetes (visit 1 or visit 2). We considered individuals with a
self-reported history of physician-diagnosed diabetes separately in all
analyses.
For analyses of prevalent retinopathy, we further excluded individuals who
did not attend visit 3 in which retinopathy was assessed, who did not receive
a retinal examination, or who had retinal photographs that were ungradable,
for a ﬁnal sample size of 9,140 (427 with a prior history of diabetes and 8,633
without). Of these, there were 767 participants (nonmissing covariates) who
also had a second eye examination 3 years after visit 3 at visit 4 (1996–98)
(13). We examined incident retinopathy (retinopathy at visit 4 among individ-
uals without retinopathy at visit 3) in this subsample.
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whole blood samples collected at ARIC visit 2 (1990–1992) for measurement
of glycated hemoglobin using high performance liquid chromatography
(Tosoh 2.2 Plus in 2003–2004 and the Tosoh G7 in 2007–2008; Tosoh
Corporation, Tokyo, Japan) (Diabetes Control and Complications Trial
[DCCT]-aligned) (14).
Incident kidney disease. We used established deﬁnitions of chronic kidney
disease in the ARIC Study (15). Speciﬁcally, we deﬁned incident chronic
kidney disease as a glomerular ﬁltration rate (GFR) 60 ml/min/1.73 m
2
estimated from serum creatinine measured at visit 4 (1996–1998), or a kidney
disease hospitalization or death identiﬁed by continuous active surveillance.
End-stage renal disease (ESRD) was comprised of the subset of hospitaliza-
tions indicating kidney transplant or dialysis (16). We conducted sensitivity
analyses to compare deﬁnitions based separately and in combination using
estimated glomerular ﬁltration rate, a creatinine rise, or a hospitalization for
kidney disease.
Prevalent retinopathy. Retinal photographs were taken at visit 3 (1993–
1995) following a standardized protocol that has been previously documented
(17,18). Brieﬂy, after 5 min of dark adaptation, a nonmydriatic 45-degree
retinal photograph centered on the optic disc and macula was taken of one
randomly selected eye. Trained readers masked to participant information
evaluated each of the photographs. A repeat retinal examination in a subset of
participants at visit 4 (3 years later) was conducted in the same eye using the
identical protocol. We deﬁned any retinopathy as a severity score 14
according to a modiﬁcation of the Airlie House classiﬁcation system, as used
in the Early Treatment Diabetic Retinopathy Study (ETDRS) (17,19). A
retinopathy severity score was assigned on the basis of the presence of lesions
and classiﬁed as follows: none (ETDRS 14), mild retinopathy (ETDRS
14–20), or moderate to severe retinopathy (ETDRS 35) (20). Incident
retinopathy was deﬁned as an ETDRS score 14 at visit 4 among individuals
who were free of retinopathy at visit 3. Mild retinopathy usually consists of
one or two microaneurysms or small hemorrhages; moderate or severe
retinopathy consists of both microaneurysms and hemorrhages, often accom-
panied by hard or soft exudates, intraretinal microvascular abnormalities,
venous beading, or less commonly vascular proliferative changes.
Other variables of interest. Methods for measurement of plasma lipids (21),
BMI kg/m
2, waist-to-hip ratio (22), and blood pressure (23) are described
elsewhere. Hypertension was deﬁned using the average of two blood pressure
readings at the visit with cut points of systolic blood pressure 140 mmHg,
diastolic blood pressure 90 mmHg, or hypertension medication use. Partic-
ipants self-reported education level (less than high school; high school or
equivalent; college or above). Smoking and alcohol drinking status were both
TABLE 1
Selected characteristics of the study population by glycated hemoglobin value at baseline*
Glycated hemoglobin category
Overall No history of diabetes Diabetes
Any 5.7% 5.7–6.5% 6.5% Any
n  11,357 n  8,095 n  2,035 n  454 n  773
Glycated hemoglobin (%) 5.7  1.1 5.3  0.3 6.0  0.2 7.4  1.4 8.1  2.3
Fasting glucose (mg/dl) 110.6  35.0 100.7  9.8 109.9  13.8 153.5  52.3 191.2  79.3
Fasting glucose category (%)
100 mg/dl 38.9 48.6 20.9 1.8 6.7
100–126 mg/dl 49.9 50.0 67.4 27.1 15.8
126 mg/dl 11.2 1.4 11.7 71.1 77.5
Age (years) 56.7  2.7 56.3  5.6 57.7  5.7 57.5  5.6 57.8  5.7
Female/male (%) 57.3/42.7 57.6/42.4 54.3/45.7 61.7/38.3 59.4/40.6
Race/ethnicity (%)
Black 23.9 15.9 42.2 52.2 42.9
White 76.1 84.1 57.8 47.8 57.1
Fasting LDL cholesterol (mg/dl) 133.0  36.5 130.7  35.5 138.7  37.4 143  39.5 136  38.9
Fasting HDL cholesterol (mg/dl) 50.4  16.6 52.1  17.1 47.4  14.7 44.0  13.7 44.7  13.6
Fasting triglycerides (mg/dl) 127.0  64.3 121.3  61.6 132.2  63.3 153.8  72.1 156.0  75.9
BMI (kg/m
2)† 27.9  5.4 26.9  4.8 29.4  5.9 32.5  6.3 30.9  6.0
Waist-to-hip ratio 0.9  0.1 0.9  0.1 0.9  0.1 1.0  0.1 1.0  0.1
Hypertension (%) 32.7 26.8 42.7 55.7 55.0
Family history of diabetes (%) 23.8 21.1 25.9 33.7 40.9
Education (%)
Less than high school 20.2 15.7 30.0 33.5 34.1
High school or equivalence 41.7 43.2 38.2 35.5 38.6
College and above 38.1 41.1 31.7 31.0 27.3
Alcohol consumption (%)
Current 57.9 63.4 49.3 40.7 35.4
Former 19.6 16.5 25.6 27.5 32.6
Never 22.5 20.1 25.1 31.7 31.9
Baecke physical activity score‡ 2.5  0.8 2.5  0.8 2.3  0.7 2.3  0.7 2.3  0.7
Smoking status (%)
Current 22.1 20.4 29.3 23.1 19.5
Former 37.0 37.8 35.3 36.3 34.4
Never 40.9 41.8 35.4 40.5 46.1
Retinopathy§
Any retinopathy (ETDRS 14) 4.67 3.02 3.85 5.16 26.53
Mild retinopathy (ETDRS 14–20) 3.02 2.66 3.08 3.15 7.04
Moderate retinopathy (ETDRS 35–43) 1.49 0.34 0.64 1.72 17.51
Severe retinopathy (ETDRS 47) 0.16 0.01 0.13 0.29 1.99
*Plus–minus values are means  SD. To convert the values for fasting glucose to millimoles per liter, multiply by 0.05551. To convert the
values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles per liter, multiply by
0.01129. †BMI is the weight in kilograms divided by the square of the height in meters. ‡Baecke’s physical activity index is measured with
the use of a questionnaire about leisure-time sports activities developed by Baecke et al. (24). The scale ranges from 1 to 4, with a score of
4 indicating the greatest activity. §Retinopathy was assessed at visit 3 in 1993–1995 (approximately 3 years after baseline). After exclusions,
n  9,140 (6,680; 1,557; 349, for glycated hemoglobin categories of 5.7%, 5.7–6.5%, and 6.5%) and 554 individuals with diabetes at visit
2.
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Baecke’s questionnaire at ARIC visit 1 (24).
Institutional Review Boards at each clinical site reviewed the study and
informed consent was obtained from all participants.
Statistical analyses. Baseline (visit 2) characteristics of the study popu-
lation were calculated overall and by 2010 American Diabetes Association
categories of glycated hemoglobin (11) (5.7%, 5.7–6.5%, or 6.5% in
individuals without a history of diabetes), and, separately, for individuals
with a history of diabetes. For analyses of incident kidney disease,
adjusted hazard ratios (HRs) and corresponding 95% CIs were estimated
using Cox proportional hazards models. For analyses of retinopathy,
adjusted odds ratios (ORs) and their corresponding 95% CIs were esti-
mated using logistic regression models. Because glycated hemoglobin was
not assessed at the same visit as the retinal examination, we report the
prevalence of retinopathy at visit 3 according to glycated hemoglobin
levels and diabetes status at visit 2.
0
20
40
60
80
100
P
r
e
v
a
l
e
n
c
e
 
o
f
 
R
e
t
i
n
o
p
a
t
h
y
 
(
%
)
<5.7% 5.7-<6.5% ≥6.5% <7.0% 7.0-<8.0% 8.0-<9.0% ≥9.0%
Glycated Hemoglobin Category 
No Diabetes  Diabetes
FIG. 1. Prevalence of any retinopathy by glycated hemoglobin category and history of diagnosed diabetes.
TABLE 2
Adjusted HRs (95% CI) for chronic kidney disease and ESRD in the study population, according to diabetes history and glycated
hemoglobin or fasting glucose clinical category
No diabetes Diabetes
Glycated hemoglobin 5.7% 5.7–6.5% 6.5% Any
Chronic kidney disease
Model 1 1.0 (ref) 1.31 (1.10–1.55) 1.84 (1.39–2.43)* 3.57 (3.00–4.25)
Model 2 1.0 (ref) 1.12 (0.94–1.34) 1.39 (1.04–1.85)* 2.73 (2.26–3.30)
ESRD
Model 1 1.0 (ref) 2.00 (1.10–3.61) 3.04 (1.31–7.09)* 13.02 (7.99–21.23)
Model 2 1.0 (ref) 1.51 (0.82–2.76) 1.98 (0.83–4.73) 7.77 (4.56–13.24)
No diabetes Diabetes
Fasting glucose 100 mg/dl 100–126 mg/dl 126 mg/dl Any
Chronic kidney disease
Model 1 1.0 (ref) 1.11 (0.96–1.30) 1.37 (1.04–1.79)* 3.47 (2.86–4.20)
Model 2 1.0 (ref) 0.98 (0.84–1.15) 0.99 (0.75–1.32) 2.50 (2.03–3.08)
ESRD
Model 1 1.0 (ref) 1.17 (0.66–2.10) 1.31 (0.48–3.55) 10.34 (5.93–18.05)
Model 2 1.0 (ref) 0.89 (0.49–1.61) 0.70 (0.25–1.95) 5.35 (2.93–9.77)
Model 1 was adjusted for age, sex, and race (black or white). Model 2 was adjusted for the variables in model 1 plus low-density and
high-density lipoprotein cholesterol levels, log-transformed triglyceride level, BMI, waist-to-hip ratio, hypertension (yes or no), family history
of diabetes (yes or no), education (less than high school, high school or equivalent, or college or above), alcohol use (currently, formerly,
or never), physical activity index score, and smoking status (current smoker, former smoker, or never smoked). *P for trend 0.05 across
clinical categories of glycated hemoglobin (5.7, 5.7–6.5, 6.5%) or fasting glucose (100, 100–126, 126 mg/dl) in individuals without
a diagnosis of diabetes.
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Model 1 was adjusted for age, sex, and race. Model 2 was adjusted for age, sex,
race, LDL- and HDL-cholesterol, triglycerides, BMI, waist-to-hip ratio, hyper-
tension, family history of diabetes, alcohol intake, education level, physical
activity, and smoking status. For comparison, we employed the same models
but substituting standard fasting glucose categories (100, 100–126, 126
mg/dl) (25) for glycated hemoglobin as the exposure of interest.
To assess the continuous associations between glycated hemoglobin and
clinical outcomes in these models, we ﬁt restricted cubic splines to the data
(26). To test for the presence of thresholds (change points) we maximized the
likelihood ratio with respect to the location of the threshold in each model and
used bootstrap methods to derive the P value for the presence of a threshold
across the range of the parameter (27). Model discrimination was assessed
using the Harrell C statistic (28) and the area under (AUC) the receiver
operator characteristic (ROC) curve. We tested for effect modiﬁcation by
race/ethnicity. We also conducted sensitivity analyses comparing deﬁnitions
of incident kidney disease (15).
RESULTS
Baseline characteristics of the study population by gly-
cated hemoglobin category and diabetes history are shown
in Table 1. Individuals without a history of diabetes who
had elevated glycated hemoglobin values at baseline were
more likely to be black than those with lower values. They
also had fewer years of education and had a more adverse
lipid proﬁle and higher BMI. During a median of 14 years
of follow-up, there were 180 and 761 incident cases of
chronic kidney disease among the 773 individuals with
diabetes and the 10,584 individuals without diabetes at
baseline, respectively. Among those individuals with an
estimated GFR 60 ml/min/1.73 m
2 at baseline, there were
47 incident cases of ESRD in individuals with diabetes,
and 55 in individuals without diabetes. The prevalence of
retinopathy at visit 3 by categories of glycated hemoglobin
stratiﬁed by diabetes status is shown in Table 1 and Fig. 1.
The prevalence of any retinopathy (ETDRS score 14) at
visit 3 in individuals with and without a history of diabetes
at visit 2 was 26.5% and 3.3%, respectively. Similarly, when
a glycated hemoglobin value of 7% was used to divide the
total population, the prevalence of any retinopathy in
individuals with glycated hemoglobin 7% was 3.3% com-
pared with 29.9% in individuals with glycated hemoglobin
7%. Note that the percentages of individuals with a
history of diabetes were 2.6% and 68.4% among individuals
with glycated hemoglobin 7% and 7%, respectively. In
the subsample of 767 individuals with retinal photography
conducted at both the visit 3 and 4 examinations, there
were 42 incident cases of retinopathy detected at the visit
4 examination (N  4 [17%] individuals with and N  38
[5%] individuals without diabetes).
We observed signiﬁcant trends of increasing risk of
chronic kidney disease and ESRD with higher values of
baseline glycated hemoglobin in individuals without a
history of diabetes even after adjustment for known risk
factors (Table 2). Among individuals without diabetes,
clinical categories of glycated hemoglobin (5.7, 5.7–
6.5, and 6.5%) were stronger predictors of chronic
kidney disease and ESRD as compared with categories
of fasting glucose (100, 100–126, and 126 mg/dl).
Diabetes history was strongly associated with risk of
chronic kidney disease and ESRD even after adjustment
(Table 2). Figure 2 depicts the adjusted HRs from the
restricted cubic spline models for chronic kidney dis-
ease by baseline glycated hemoglobin value in the total
population and, separately, in nondiabetic and diabetic
participants. The restricted cubic spline models for the
association of fasting glucose are presented in supple-
mentary Fig. 1 in the online appendix available at
http://diabetes.diabetesjournals.org/cgi/content/full/db10-
1198/DC1. The C statistics from the unadjusted Cox model
for glycated hemoglobin (modeled continuously) and risk
of chronic kidney disease in the total population, diabetic
participants, and nondiabetic participants were 0.608,
0.644, and 0.562, respectively. The C statistics for ESRD
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FIG. 2. Adjusted HR of incident chronic kidney disease according to
baseline glycated hemoglobin value. The ﬁgures show adjusted HRs
from restricted cubic spline models. The shaded area is the 95% CI. The
models are centered at the median (5.5%, 5.4%, and 7.4% in the total
population, nondiabetic, and diabetic participants, respectively) and
truncated at the 2.5th and the 97.5th percentiles of glycated hemoglo-
bin in each population. The HRs were adjusted for age, sex, and race
(black or white), low-density and high-density cholesterol levels, log
transformed triglyceride level, BMI, waist-to-hip ratio, hypertension
(yes or no), family history of diabetes (yes or no), education (less than
high school, high school or equivalent, or college or above), alcohol use
(currently, formerly, or never), physical activity index score, and
smoking status (current smoker, former smoker, or never smoked).
The model in A is further adjusted for diabetes medication use. The
data are shown on a natural-log scale. (A high-quality color represen-
tation of this ﬁgure is available in the online issue.)
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for fasting glucose and risk of chronic kidney disease in
the total population, diabetic participants, and nondiabetic
participants were 0.591, 0.624 and 0.541, respectively; and
0.521, 0.575, and 0.566, respectively, for ESRD.
Among individuals without a history of diabetes, gly-
cated hemoglobin was cross-sectionally associated with
moderate to severe retinopathy (ETDRS score 35) (Ta-
ble 3 and Fig. 3), although its presence was very rare in the
absence of diagnosed diabetes (0.5%). However, there was
no association between glycated hemoglobin or fasting
glucose and prevalence of any retinopathy or mild retinop-
athy after adjustment for covariates (Table 3 and the
online appendix). By contrast, vascular risk factors were
signiﬁcantly and independently associated with any reti-
nopathy and mild retinopathy in individuals without a
history of diabetes. Hypertension, in particular, was ro-
bustly associated with any retinopathy (OR 1.54 [1.24–
1.92]) and mild retinopathy (OR 1.39 [1.07–1.81]) in fully
adjusted models among nondiabetic adults. Among indi-
viduals with diabetes, glycated hemoglobin was robustly
associated with all levels of retinopathy (any, mild, and
moderate/severe) (Figs. 1, 3, and the online appendix).
Indeed, in individuals with diagnosed diabetes, the ad-
justed ORs (model 2) for any retinopathy were 3.79
(1.80–7.99), 8.41 (4.00–17.81), and 18.56 (9.54–36.13) com-
paring baseline glycated hemoglobin categories 7.0–8.0,
8.0–9.0, and 9.0% to 7.0% The corresponding adjusted
ORs for mild retinopathy were 3.18 (1.09–9.28), 3.95
(1.21–12.92), and 7.86 (2.93–21.07), respectively.
The unadjusted AUCs for glycated hemoglobin or fasting
glucose for the detection of retinopathy are shown in Table 4.
The highest AUCs were observed in individuals with a history
of diabetes with the exception of moderate/severe retinopa-
thy, which was highest in the overall population, reﬂecting
the substantially high speciﬁcity of severe/moderate retinop-
athy for hyperglycemia.
The adjusted ORs (model 2) for incident retinopathy at
visit 4 by baseline category of glycated hemoglobin were 1.54
(0.51–4.60), 3.51 (0.70–17.51), and 4.43 (1.31–14.91) for 5.7–
6.5%, 6.5%, and diagnosed diabetes, respectively, as com-
pared with glycated hemoglobin 5.7% in individuals without
diagnosed diabetes. The AUC for incident retinopathy was
0.617 (0.482–0.751). In this subsample, the number of indi-
viduals with diagnosed diabetes at baseline was too small to
precisely estimate the effect of glycated hemoglobin on
incident retinopathy separately in this group.
There was no evidence for the presence of a glycated
hemoglobin threshold for any of the microvascular out-
comes before or after adjustment for covariates (all P
values 0.40, see supplementary Table 1 and supplemen-
tary Table 2). There were no signiﬁcant interactions for
race/ethnicity in the association of glycated hemoglobin
with chronic kidney disease or retinopathy in individuals
with or without diabetes in any of the spline models (all P
values for interaction 0.40 for the fully adjusted models).
The C statistics and AUCs for the different models were
also not appreciably different by race/ethnicity (data not
shown).
TABLE 3
Adjusted ORs (95% CI) for retinopathy† in the study population, according to diabetes history and glycated hemoglobin or fasting
glucose clinical category
No diabetes Diabetes
Glycated hemoglobin 5.7% 5.7–6.5% 6.5% Any
Retinopathy
Any (ETDRS 14)
Model 1 1.0 (ref) 0.98 (0.73–1.33) 1.25 (0.75–2.07) 9.41 (7.38–12.00)
Model 2 1.0 (ref) 0.84 (0.61–1.14) 0.91 (0.54–1.54) 7.07 (5.40–9.24)
Mild (ETDRS 14–20)
Model 1 1.0 (ref) 0.88 (0.62–1.23) 0.85 (0.45–1.60) 2.77 (1.91–4.01)
Model 2 1.0 (ref) 0.77 (0.54–1.08) 0.65 (0.34–1.23) 2.21 (1.49–3.27)
Moderate/severe (ETDRS 35)
Model 1 1.0 (ref) 1.76 (0.87–3.57) 4.35 (1.83–10.31)* 56.96 (35.8–90.58)
Model 2 1.0 (ref) 1.42 (0.69–2.92) 2.91 (1.19–7.11)* 38.81 (23.38–64.39)
 diabetes Diabetes
Fasting glucose 100 mg/dl 100–126 mg/dl 126 mg/dl Any
Retinopathy
Any (ETDRS 14)
Model 1 1.0 (ref) 1.25 (0.96–1.63) 1.71 (1.10–2.64)* 11.05 (8.32–14.70)
Model 2 1.0 (ref) 1.11 (0.84–1.45) 1.28 (0.81–2.02) 8.22 (6.01–11.25)
Mild (ETDRS 14–20)
Model 1 1.0 (ref) 1.22 (0.92–1.62) 1.47 (0.90–2.41) 3.47 (2.24–5.01)
Model 2 1.0 (ref) 1.10 (0.83–1.48) 1.15 (0.68–1.93) 2.69 (1.75–4.14)
Moderate/severe (ETDRS 35)
Model 1 1.0 (ref) 1.38 (0.69–2.73) 3.18 (1.26–8.07)* 57.31 (31.67–103.72)
Model 2 1.0 (ref) 1.14 (0.57–2.29) 2.13 (0.82–5.56) 36.40 (19.26–68.80)
Model 1 was adjusted for age, sex, and race (black or white). Model 2 was adjusted for the variables in model 1 plus low-density and
high-density lipoprotein cholesterol levels, log-transformed triglyceride level, BMI, waist-to-hip ratio, hypertension (yes or no), family history
of diabetes (yes or no), education (less than high school, high school or equivalent, or college or above), alcohol use (currently, formerly,
or never), physical activity index score, and smoking status (current smoker, former smoker, or never smoked). *P for trend 0.05 across
clinical categories of glycated hemoglobin (5.7, 5.7–6.5, 6.5%) or fasting glucose (100, 100–126, 126 mg/dl) in individuals without
a diagnosis of diabetes. †Retinopathy was assessed at visit 3 in 1993–1995 (3 years after baseline).
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These data provide evidence for the following conclu-
sions: 1) the new 2010 American Diabetes Association
glycated hemoglobin cut points predict future risk of
kidney disease and are associated with prevalent retinop-
athy, even after adjustment for known risk factors; 2)
although risk was clearly strongest among individuals with
a history of diabetes, we were unable to ﬁrmly demon-
strate the presence of a natural “glycemic threshold” in
these data (3,11); and 3) in this community-based popula-
tion, glycated hemoglobin performed as well as fasting
glucose, and was superior in some circumstances, for
identifying individuals at risk for microvascular outcomes.
Few studies have examined the prospective association
of glycated hemoglobin with incident kidney disease in the
absence of diagnosed diabetes (29). We previously dem-
onstrated an independent association between glycated
hemoglobin and risk of chronic kidney disease in individ-
uals with diabetes even in the absence of albuminuria and
retinopathy in the ARIC Study (30). In the present study,
elevated values of glycated hemoglobin at baseline were
associated with an increased risk of chronic kidney dis-
ease even in the absence of a diagnosis of diabetes, and
glycated hemoglobin was a better predictor as compared
with fasting glucose.
Our results are consistent with other recent studies
(31–33) and are relevant to the controversy regarding the
presence of a “glycemic threshold” for retinopathy, i.e., the
presence of a threshold below which glycemia is not
strongly associated with retinopathy and above which
there is clear association (3,11). This evidence is primarily
based on three early epidemiologic studies (4,5,34). Re-
cent studies that employed more sensitive techniques for
the identiﬁcation of retinopathy, however, indicate that
the association between glycemia and retinopathy is con-
tinuous with no clear natural threshold (2,35). One difﬁ-
culty in interpretation of the literature is that prior studies
have examined this association in a mixed population of
individuals with and without diabetes. Examining the
cross-sectional association of glycated hemoglobin and
prevalent retinopathy in populations that include individ-
uals with diabetes who may have received lifestyle and/or
pharmacologic interventions to lower glycated hemoglo-
bin is problematic; the onset of microvascular disease may
have occurred years earlier and the “risk thresholds”
observed for glycated hemoglobin in these studies may not
accurately reﬂect values at which risk begins to increase.
We showed the relationships of glycated hemoglobin and
microvascular disease end points separately, in diabetic
and nondiabetic individuals, demonstrating differential
associations of glycated hemoglobin with retinopathy in
diabetic (strong association with mild retinopathy) and
nondiabetic individuals (weak or no association).
Although the ETDRS classiﬁcation system may have
limitations for deﬁning retinopathy in individuals with-
out diabetes (36), the lack of association between mild
retinopathy and glycemia and the robust associations
with hypertension in individuals without diabetes sug-
gests that the early retinal abnormalities of microaneu-
rysms and retinal hemorrhages have a hypertensive or
other etiology (37). Our results highlight the difﬁculty in
deﬁning “diabetic retinopathy” in a nondiabetic popula-
tion and speak to the need for long-term prospective
studies of microvascular disease in initially nondiabetic
adults.
Limitations that should be considered in the interpreta-
tion of these data include the following: retinal photo-
graphs were taken in only one eye, which may have
resulted in low sensitivity for the detection of retinopathy
(2), leading to misclassiﬁcation of cases as noncases.
Further, the retinal exam in all ARIC participants was
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FIG. 3. Adjusted OR of prevalent moderate/severe retinopathy*
(ETDRS >35) according to baseline glycated hemoglobin value. The
ﬁgures show adjusted ORs from restricted cubic spline models. The
shaded area is the 95% CI. The models are centered at the median
(5.5%, 5.4%, and 7.4% in the total population, nondiabetic, and dia-
betic participants, respectively) and truncated at the 2.5th and the
97.5th percentiles of glycated hemoglobin. The ORs were adjusted for
age, sex, and race (black or white), low-density and high-density
cholesterol levels, log-transformed triglyceride level, BMI, waist-to-hip
ratio, hypertension (yes or no), family history of diabetes (yes or no),
education (less than high school, high school or equivalent, or college
or above), alcohol use (currently, formerly, or never), physical activity
index score, and smoking status (current smoker, former smoker, or
never smoked). The model in panel A is further adjusted for diabetes
medication use. The data are shown on a natural-log scale. *Retinopa-
thy was assessed at visit 3 in 1993–1995 (3 years after baseline). (A
high-quality color representation of this ﬁgure is available in the
online issue.)
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ments are only available at visit 2 (3 years earlier). We also
only had serum creatinine measured during one subse-
quent visit for the detection of decreased kidney function
to deﬁne kidney disease. And as with all observational
studies, we cannot eliminate the possibility of residual
confounding. Strengths of this study include the large and
diverse community-based sample, the availability of both
fasting glucose and glycated hemoglobin measurements,
the rigorous measurement of potentially confounding fac-
tors, and the prospective follow-up of participants with
high retention (90%).
In conclusion, these data from a community-based,
biracial population support the use of new 2010 American
Diabetes Association glycated hemoglobin cut points for
the diagnosis of diabetes.
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